Novacyt Stock

Novacyt Working Capital

The Working Capital of Novacyt (ALNOV.PA) as of Sep 5, 2026 is 29.39 M GBP. In the previous year, Working Capital was 56.88 M GBP — a change of -48.33% (lower).

Working Capital

29.39 MGBP

YoY

-48.33%

Last updated:

Working Capital of Novacyt is 2026 29.39 M GBP. Working Capital of Novacyt was 2025 56.88 M GBP. It decreases by -48.33% lower compared to the previous year.
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Working Capital of Novacyt is 29.39 M GBP in 2026.

Working Capital of Novacyt changed from 56.88 M GBP to 29.39 M GBP, representing a -48.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Novacyt since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Novacyt historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novacyt

All Key Metrics — Novacyt